Zacks Investment Research lowered shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a sell rating in a report published on Thursday.
According to Zacks, “Theravance received a huge boost when the FDA approved Yupelri, the first once daily nebulized LAMA option for COPD, in November. The company plans to launch the drug by 2018 end. Meanwhile, the agreement to divest its only marketed drug, Vibativ, will enable Theravance to focus solely on the launch efforts of Yupelri. Moreover, its pipeline programs target highly competitive therapeutic areas. The company's collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as was the case in the past. Shares of the company have outperformed the industry in the past year.”
Several other analysts also recently commented on TBPH. BidaskClub upgraded shares of Theravance Biopharma from a buy rating to a strong-buy rating in a research report on Thursday. ValuEngine upgraded shares of Theravance Biopharma from a hold rating to a buy rating in a research report on Friday, November 30th. Leerink Swann set a $38.00 price target on shares of Theravance Biopharma and gave the company a buy rating in a research report on Wednesday, November 7th. Cantor Fitzgerald reiterated a buy rating and issued a $55.00 price target on shares of Theravance Biopharma in a research report on Friday, November 9th. Finally, Piper Jaffray Companies reiterated a buy rating on shares of Theravance Biopharma in a research report on Tuesday, October 23rd. One analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $43.40.
Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.18) by $0.08. Theravance Biopharma had a negative net margin of 513.41% and a negative return on equity of 505.90%. The firm had revenue of $12.84 million during the quarter, compared to the consensus estimate of $10.55 million. On average, equities research analysts forecast that Theravance Biopharma will post -4.18 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in TBPH. Candriam Luxembourg S.C.A. acquired a new position in Theravance Biopharma in the 3rd quarter valued at $8,321,000. BlackRock Inc. increased its stake in Theravance Biopharma by 4.7% in the 2nd quarter. BlackRock Inc. now owns 3,750,789 shares of the biopharmaceutical company’s stock valued at $85,066,000 after buying an additional 167,747 shares during the period. Vanguard Group Inc increased its stake in Theravance Biopharma by 3.6% in the 3rd quarter. Vanguard Group Inc now owns 3,672,030 shares of the biopharmaceutical company’s stock valued at $119,965,000 after buying an additional 126,135 shares during the period. Vanguard Group Inc. increased its stake in Theravance Biopharma by 3.6% in the 3rd quarter. Vanguard Group Inc. now owns 3,672,030 shares of the biopharmaceutical company’s stock valued at $119,965,000 after buying an additional 126,135 shares during the period. Finally, Ibex Investors LLC acquired a new position in Theravance Biopharma in the 3rd quarter valued at $1,506,000. 83.93% of the stock is currently owned by institutional investors.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.